Deleterious Effect of Prednisolone in HBsAg-positive Chronic Active Hepatitis

To study the efficacy of corticosteroids in chronic active hepatitis (CAH) positive for hepatitis B surface antigen (HBsAg), we pair-randomized 51 patients to receive either 15 to 20 mg of prednisolone per day or a placebo. After initial remission, the maintenance dosage of prednisolone was 10 mg pe...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 1981-02, Vol.304 (7), p.380-386
Hauptverfasser:	Lam, Kui Chun, Lai, Ching Lung, Ng, R. P, Trepo, Christian, Wu, P. C
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Alanine Transaminase - blood Aspartate Aminotransferases - blood Bilirubin - blood Biopsy Chronic Disease Clinical Trials as Topic Corticosteroids Diabetes Drug dosages Endoscopy Female Hepatitis Hepatitis - drug therapy Hepatitis B - drug therapy Hepatitis B Surface Antigens - analysis Hospitals Humans Laboratories Male Middle Aged Patients Prednisolone - adverse effects Prednisolone - therapeutic use Prospective Studies Random Allocation Remission, Spontaneous Serum Globulins - analysis Tuberculosis Urine
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	To study the efficacy of corticosteroids in chronic active hepatitis (CAH) positive for hepatitis B surface antigen (HBsAg), we pair-randomized 51 patients to receive either 15 to 20 mg of prednisolone per day or a placebo. After initial remission, the maintenance dosage of prednisolone was 10 mg per day, and the patients were prospectively followed for up to 3 1/2 years. Prednisolone decreased serum bilirubin (P
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJM198102123040702